DelveInsight’s “Diabetes Pipeline Insight 2026” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in the Diabetes pipeline landscape. It covers the Diabetes pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diabetes therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment options in the Diabetes Pipeline @ Diabetes Pipeline Outlook
Key Takeaways from the Diabetes Pipeline Report
Get insights into Diabetes Clinical Trials, emerging therapies, and leading companies with DelveInsight @ Diabetes Treatment Drugs
The Diabetes Pipeline Report provides a disease overview, pipeline scenario, and therapeutic assessment of the key pipeline therapies in this domain. The Diabetes Pipeline Report also highlights the unmet needs with respect to the Diabetes.
Diabetes Overview
Diabetes is a chronic metabolic disorder characterized by high blood sugar levels due to the body’s inability to produce or effectively use insulin, a hormone essential for regulating glucose. The disease primarily exists in two main forms: Type 1 diabetes, an autoimmune condition where the immune system attacks insulin-producing cells in the pancreas, and Type 2 diabetes, which is more common and often associated with insulin resistance and lifestyle factors such as obesity and poor diet. Other types include gestational diabetes, which occurs during pregnancy, and rarer forms such as Maturity-Onset Diabetes of the Young (MODY) and Latent Autoimmune Diabetes in Adults (LADA).
Diabetes Emerging Drugs Profile
Retatrutide is an investigational once-weekly triple hormone receptor agonist. Retatrutide is a single molecule that activates the body’s receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. Retatrutide has a unique mechanism of action in the increasingly popular class of incretin mimetics. As a novel triple agonist, it harnesses the action of the three peptide hormones GLP-1, GIP, and GCG. Like other incretin mimetics, it is structurally similar to GIP, with alterations in the peptide backbone to increase agonist activity at the GIP, GLP-1, and GCG receptors. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Diabetes.
CT-388 is an investigational once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed for the treatment of obesity, type 2 diabetes, and other obesity-related comorbidities. It aims to reduce appetite and regulate blood sugar by selectively targeting and activating both receptors which integrate nutrient-derived signals to control energy homeostasis. CT-388 was designed to have potent activation of both GLP-1 and GIP receptors, but with minimal to no ß-arrestin recruitment on either receptor. This biased signaling significantly minimises receptor internalisation and consequent desensitization, which is expected to lead to prolonged pharmacological activity. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Diabetes.
AZD5004 is an investigational drug being developed by AstraZeneca as a novel, once-daily oral small-molecule glucagon-like peptide-1 (GLP-1) receptor agonist. it is designed for the treatment of cardiometabolic conditions such as type 2 diabetes mellitus and obesity. Unlike many existing GLP-1 therapies that are injectable peptides, AZD5004 is a non-peptide oral agent that activates GLP-1 receptors to enhance insulin secretion, improve glucose control, and promote weight loss. Early clinical and preclinical studies have shown that the drug is generally well tolerated and produces dose-dependent reductions in blood glucose and body weight, supporting its continued development in Phase II trials for obesity and related metabolic disorders. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Diabetes.
Brivekimig (SAR442970) is a dual-target Nanobody® molecule inhibiting the tumor necrosis factor and OX40-ligand, key immune regulators. It is being investigated for potential uses across a range of immune-mediated diseases and inflammatory disorders. As a VHH antibody (Nanobody), it binds to and inhibits both TNF and OX40L, which reduces inflammation by preventing T-cell activation which helps in treatment of Diabetes. Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Diabetes.
MTX-101 is a first-in-class bispecific antibody designed to modulate the immune system by activating CD8 regulatory T cells, which help suppress the autoimmune response responsible for destroying insulin-producing pancreatic beta cells. MTX-101 aims to address the root cause of the disease by restoring immune balance and potentially slowing or halting disease progression. Early findings suggest it is generally well tolerated and biologically active. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Diabetes.
CNTY-813 is comprised of iPSC-derived beta islets engineered with Allo-Evasion™ 5.0 and designed to protect from T cell, NK cell and humoral immune rejection, with the goal of durable glycemic control without the need for systemic immunosuppression. The mechanism of action is based on transplantation of these functional β-cells, which respond to blood glucose levels by secreting insulin (glucose-stimulated insulin secretion), thereby helping normalize glycemic control. Currently, the drug is being evaluated in the preclinical stage of its development for the treatment of Diabetes.
Explore groundbreaking therapies and clinical trials in the Diabetes Pipeline @ New Diabetes Drugs
The Diabetes Pipeline Report Provides Insights into
Diabetes Companies
Eli Lilly and Company, F. Hoffmann-La Roche Ltd., AstraZeneca, Mozart Therapeutics, Sanofi, Century Therapeutics, Dong-A ST Co., Ltd., Novo Nordisk A/S, Zealand Pharma, Diamyd Medical, Vactech, Adocia, Tonghua Dongbao Pharmaceutical, Gasherbrum Bio, Inc. (a wholly owned subsidiary of Structure Therapeutics), Vivani Medical Inc., Imcyse, Amgen Inc., Vertex Pharmaceuticals Incorporated, Oramed, Gilead Sciences, Cadrenal Therapeutics, Inc., and TIXiMED and others.
The Diabetes pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Diabetes Products have been categorized under various Molecule types such as,
Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Diabetes Market Drivers and Barriers
Scope of the Diabetes Pipeline Report
Download DelveInsight’s in-depth pipeline report today! @ Diabetes Companies, Key Products and Unmet Needs
Table of Contents
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/report-store/diabetes-pipeline-insight
